260 related articles for article (PubMed ID: 25849327)
1. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy.
Lei J; Rudolph A; Moysich KB; Rafiq S; Behrens S; Goode EL; Pharoah PP; Seibold P; Fasching PA; Andrulis IL; Kristensen VN; Couch FJ; Hamann U; Hooning MJ; Nevanlinna H; Eilber U; Bolla MK; Dennis J; Wang Q; Lindblom A; Mannermaa A; Lambrechts D; García-Closas M; Hall P; Chenevix-Trench G; Shah M; Luben R; Haeberle L; Ekici AB; Beckmann MW; Knight JA; Glendon G; Tchatchou S; Alnæs GI; Borresen-Dale AL; Nord S; Olson JE; Hallberg E; Vachon C; Torres D; Ulmer HU; Rüdiger T; Jager A; van Deurzen CH; Tilanus-Linthorst MM; Muranen TA; Aittomäki K; Blomqvist C; Margolin S; Kosma VM; Hartikainen JM; Kataja V; Hatse S; Wildiers H; Smeets A; Figueroa J; Chanock SJ; Lissowska J; Li J; Humphreys K; Phillips KA; ; Linn S; Cornelissen S; van den Broek SA; Kang D; Choi JY; Park SK; Yoo KY; Hsiung CN; Wu PE; Hou MF; Shen CY; Teo SH; Taib NA; Yip CH; Ho GF; Matsuo K; Ito H; Iwata H; Tajima K; Dunning AM; Benitez J; Czene K; Sucheston LE; Maishman T; Tapper WJ; Eccles D; Easton DF; Schmidt MK; Chang-Claude J
Breast Cancer Res; 2015 Feb; 17(1):18. PubMed ID: 25849327
[TBL] [Abstract][Full Text] [Related]
2. Clinical Characteristics and Outcomes of Single Versus Double Hormone Receptor-Positive Breast Cancer in 2 Large Databases.
Li Z; Tu Y; Wu Q; Wang Z; Li J; Zhang Y; Sun S
Clin Breast Cancer; 2020 Apr; 20(2):e151-e163. PubMed ID: 31551181
[TBL] [Abstract][Full Text] [Related]
3. Pathway analyses identify TGFBR2 as potential breast cancer susceptibility gene: results from a consortium study among Asians.
Ma X; Beeghly-Fadiel A; Lu W; Shi J; Xiang YB; Cai Q; Shen H; Shen CY; Ren Z; Matsuo K; Khoo US; Iwasaki M; Long J; Zhang B; Ji BT; Zheng Y; Wang W; Hu Z; Liu Y; Wu PE; Shieh YL; Wang S; Xie X; Ito H; Kasuga Y; Chan KY; Iwata H; Tsugane S; Gao YT; Shu XO; Moses HL; Zheng W
Cancer Epidemiol Biomarkers Prev; 2012 Jul; 21(7):1176-84. PubMed ID: 22539603
[TBL] [Abstract][Full Text] [Related]
4. High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes.
Riaz M; Sieuwerts AM; Look MP; Timmermans MA; Smid M; Foekens JA; Martens JW
Breast Cancer Res; 2012 Sep; 14(5):R123. PubMed ID: 22967435
[TBL] [Abstract][Full Text] [Related]
5. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.
Iwamoto T; Bianchini G; Booser D; Qi Y; Coutant C; Shiang CY; Santarpia L; Matsuoka J; Hortobagyi GN; Symmans WF; Holmes FA; O'Shaughnessy J; Hellerstedt B; Pippen J; Andre F; Simon R; Pusztai L
J Natl Cancer Inst; 2011 Feb; 103(3):264-72. PubMed ID: 21191116
[TBL] [Abstract][Full Text] [Related]
6. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.
Bianchini G; Qi Y; Alvarez RH; Iwamoto T; Coutant C; Ibrahim NK; Valero V; Cristofanilli M; Green MC; Radvanyi L; Hatzis C; Hortobagyi GN; Andre F; Gianni L; Symmans WF; Pusztai L
J Clin Oncol; 2010 Oct; 28(28):4316-23. PubMed ID: 20805453
[TBL] [Abstract][Full Text] [Related]
7. Absence of transforming growth factor-beta type II receptor is associated with poorer prognosis in HER2-negative breast tumours.
Paiva CE; Drigo SA; Rosa FE; Moraes Neto FA; Caldeira JRF; Soares FA; Domingues MAC; Rogatto SR
Ann Oncol; 2010 Apr; 21(4):734-740. PubMed ID: 19914962
[TBL] [Abstract][Full Text] [Related]
8. A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients.
Seibold P; Schmezer P; Behrens S; Michailidou K; Bolla MK; Wang Q; Flesch-Janys D; Nevanlinna H; Fagerholm R; Aittomäki K; Blomqvist C; Margolin S; Mannermaa A; Kataja V; Kosma VM; Hartikainen JM; Lambrechts D; Wildiers H; Kristensen V; Alnæs GG; Nord S; Borresen-Dale AL; Hooning MJ; Hollestelle A; Jager A; Seynaeve C; Li J; Liu J; Humphreys K; Dunning AM; Rhenius V; Shah M; Kabisch M; Torres D; Ulmer HU; Hamann U; Schildkraut JM; Purrington KS; Couch FJ; Hall P; Pharoah P; Easton DF; Schmidt MK; Chang-Claude J; Popanda O
BMC Cancer; 2015 Dec; 15():978. PubMed ID: 26674097
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
10. CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.
Dietrich D; Krispin M; Dietrich J; Fassbender A; Lewin J; Harbeck N; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Spyratos F; Foekens JA; Lesche R; Martens JW
BMC Cancer; 2010 Jun; 10():247. PubMed ID: 20515469
[TBL] [Abstract][Full Text] [Related]
11. Prospective observational study of breast cancer treatment outcomes for UK women aged 18-40 years at diagnosis: the POSH study.
Copson E; Eccles B; Maishman T; Gerty S; Stanton L; Cutress RI; Altman DG; Durcan L; Simmonds P; Lawrence G; Jones L; Bliss J; Eccles D;
J Natl Cancer Inst; 2013 Jul; 105(13):978-88. PubMed ID: 23723422
[TBL] [Abstract][Full Text] [Related]
12. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
13. TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers.
Shima K; Morikawa T; Yamauchi M; Kuchiba A; Imamura Y; Liao X; Meyerhardt JA; Fuchs CS; Ogino S
PLoS One; 2011; 6(9):e25062. PubMed ID: 21949851
[TBL] [Abstract][Full Text] [Related]
14. SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.
Abdel-Fatah TMA; Agarwal D; Liu DX; Russell R; Rueda OM; Liu K; Xu B; Moseley PM; Green AR; Pockley AG; Rees RC; Caldas C; Ellis IO; Ball GR; Chan SYT
Lancet Oncol; 2016 Jul; 17(7):1004-1018. PubMed ID: 27312051
[TBL] [Abstract][Full Text] [Related]
15. The prognostic effect of estrogen receptor status differs for younger versus older breast cancer patients.
Sopik V; Sun P; Narod SA
Breast Cancer Res Treat; 2017 Sep; 165(2):391-402. PubMed ID: 28601929
[TBL] [Abstract][Full Text] [Related]
16. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
Regan MM; Pagani O; Francis PA; Fleming GF; Walley BA; Kammler R; Dell'Orto P; Russo L; Szőke J; Doimi F; Villani L; Pizzolitto S; Öhlschlegel C; Sessa F; Peg Cámara V; Rodríguez Peralto JL; MacGrogan G; Colleoni M; Goldhirsch A; Price KN; Coates AS; Gelber RD; Viale G;
Breast Cancer Res Treat; 2015 Nov; 154(2):275-86. PubMed ID: 26493064
[TBL] [Abstract][Full Text] [Related]
17. TGF-beta receptor type-2 expression in cancer-associated fibroblasts regulates breast cancer cell growth and survival and is a prognostic marker in pre-menopausal breast cancer.
Busch S; Acar A; Magnusson Y; Gregersson P; Rydén L; Landberg G
Oncogene; 2015 Jan; 34(1):27-38. PubMed ID: 24336330
[TBL] [Abstract][Full Text] [Related]
18. CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
Leyland-Jones B; Gray KP; Abramovitz M; Bouzyk M; Young B; Long B; Kammler R; Dell'Orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Harvey VJ; Neven P; Treilleux I; Rasmussen BB; Maibach R; Price KN; Coates AS; Goldhirsch A; Pagani O; Viale G; Rae JM; Regan MM
Breast Cancer Res Treat; 2015 Jun; 151(2):373-84. PubMed ID: 25935582
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
Loi S; Sirtaine N; Piette F; Salgado R; Viale G; Van Eenoo F; Rouas G; Francis P; Crown JP; Hitre E; de Azambuja E; Quinaux E; Di Leo A; Michiels S; Piccart MJ; Sotiriou C
J Clin Oncol; 2013 Mar; 31(7):860-7. PubMed ID: 23341518
[TBL] [Abstract][Full Text] [Related]
20. Impact of triple negative phenotype on breast cancer prognosis.
Kaplan HG; Malmgren JA
Breast J; 2008; 14(5):456-63. PubMed ID: 18657139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
